520 related articles for article (PubMed ID: 18760581)
1. Economic burden prior to COPD diagnosis: a matched case-control study in the United States.
Akazawa M; Halpern R; Riedel AA; Stanford RH; Dalal A; Blanchette CM
Respir Med; 2008 Dec; 102(12):1744-52. PubMed ID: 18760581
[TBL] [Abstract][Full Text] [Related]
2. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.
Menzin J; Boulanger L; Marton J; Guadagno L; Dastani H; Dirani R; Phillips A; Shah H
Respir Med; 2008 Sep; 102(9):1248-56. PubMed ID: 18620852
[TBL] [Abstract][Full Text] [Related]
3. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
4. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
5. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
6. Cost and utilization of COPD and asthma among insured adults in the US.
Blanchette CM; Broder M; Ory C; Chang E; Akazawa M; Dalal AA
Curr Med Res Opin; 2009 Jun; 25(6):1385-92. PubMed ID: 19419342
[TBL] [Abstract][Full Text] [Related]
7. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
8. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD.
Lin PJ; Shaya FT; Scharf SM
Respir Med; 2010 May; 104(5):697-704. PubMed ID: 19954941
[TBL] [Abstract][Full Text] [Related]
9. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.
Akazawa M; Biddle AK; Stearns SC
Clin Ther; 2008; 30 Spec No():1003-16. PubMed ID: 18640475
[TBL] [Abstract][Full Text] [Related]
10. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
11. Chronic obstructive pulmonary disease surveillance--United States, 1971-2000.
Mannino DM; Homa DM; Akinbami LJ; Ford ES; Redd SC
Respir Care; 2002 Oct; 47(10):1184-99. PubMed ID: 12354338
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
13. Health service utilization among Alzheimer's disease patients: evidence from managed care.
Frytak JR; Henk HJ; Zhao Y; Bowman L; Flynn JA; Nelson M
Alzheimers Dement; 2008 Sep; 4(5):361-7. PubMed ID: 18790463
[TBL] [Abstract][Full Text] [Related]
14. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
Akazawa M; Hayflinger DC; Stanford RH; Blanchette CM
Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095
[TBL] [Abstract][Full Text] [Related]
15. The cost of treating patients with COPD in Denmark--a population study of COPD patients compared with non-COPD controls.
Bilde L; Rud Svenning A; Dollerup J; Baekke Borgeskov H; Lange P
Respir Med; 2007 Mar; 101(3):539-46. PubMed ID: 16889949
[TBL] [Abstract][Full Text] [Related]
16. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.
Mittmann N; Kuramoto L; Seung SJ; Haddon JM; Bradley-Kennedy C; Fitzgerald JM
Respir Med; 2008 Mar; 102(3):413-21. PubMed ID: 18086519
[TBL] [Abstract][Full Text] [Related]
17. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.
Insinga RP; Ye X; Singhal PK; Carides GW
Gynecol Oncol; 2008 Nov; 111(2):188-96. PubMed ID: 18757080
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of chronic obstructive pulmonary disease.
Teo WS; Tan WS; Chong WF; Abisheganaden J; Lew YJ; Lim TK; Heng BH
Respirology; 2012 Jan; 17(1):120-6. PubMed ID: 21954985
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease.
Dalal AA; Shah M; Lunacsek O; Hanania NA
Respir Med; 2011 Oct; 105(10):1516-22. PubMed ID: 21684731
[TBL] [Abstract][Full Text] [Related]
20. The direct medical costs of undiagnosed chronic obstructive pulmonary disease.
Mapel DW; Robinson SB; Dastani HB; Shah H; Phillips AL; Lydick E
Value Health; 2008; 11(4):628-36. PubMed ID: 18194402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
